Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incidence and Predictors of Esophagogastric Varices Bleeding in Patients with Hepatocellular Carcinoma in Lenvatinib
Authors
Keywords
-
Journal
Liver Cancer
Volume -, Issue -, Pages 1-12
Publisher
S. Karger AG
Online
2023-10-12
DOI
10.1159/000534127
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept
- (2023) Alessandro Vitale et al. LANCET ONCOLOGY
- Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function
- (2022) Giuseppe Cabibbo et al. DIGESTIVE AND LIVER DISEASE
- Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: A real‐world study
- (2022) Antonio D’Alessio et al. HEPATOLOGY
- IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.
- (2021) Valeriy Vladimirovich Breder et al. JOURNAL OF CLINICAL ONCOLOGY
- Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
- (2021) Ilario Giovanni Rapposelli et al. LIVER INTERNATIONAL
- Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses…
- (2021) Manon Allaire et al. LIVER INTERNATIONAL
- Baveno VII – Renewing consensus in portal hypertension
- (2021) Roberto de Franchis et al. JOURNAL OF HEPATOLOGY
- Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib
- (2021) M. Rimini et al. ESMO Open
- BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
- (2021) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Portal hemodynamic effects of lenvatinib in patients with advanced hepatocellular carcinoma: A prospective cohort study
- (2020) Hisashi Hidaka et al. HEPATOLOGY RESEARCH
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
- (2016) Jorge A. Marrero et al. JOURNAL OF HEPATOLOGY
- Expanding consensus in portal hypertension
- (2015) Roberto de Franchis JOURNAL OF HEPATOLOGY
- Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2015) Massimo Iavarone et al. United European Gastroenterology Journal
- Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials
- (2012) Ping Fang et al. PLoS One
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More